- Oncology consultancy Physiomics said it had won a new contract from Japanese pharmaceutical company Astellas Pharma.

Physiomics said the precise value of the contract could not be disclosed for reasons of commercial confidentiality, however it was around 20% of the company's annual income for the year through June 2019.

The contract was for a modelling project involving Physiomics' Virtual Tumour immuno-oncology model and the work was expected to be completed this calendar year.

At 9:04am: [LON:PYC] Physiomics PLC share price was -1.25p at 8.05p

Story provided by